Furui: Ali Health's target price is lowered to 5.3 Hong Kong dollars, reiterates "buy" rating.

Furui released a research report stating that Ali Health's "Hydrogen Ion" app is positioned as an early AI leader for doctors, partnering with the British Medical Journal to provide evidence-based clinical decision support. Initial product testing shows strong usability, low illusion rate, and robust clinical reasoning. Management expects to invest 200 to 300 million yuan in AI research and development annually from 2027 to 2029 fiscal years, targeting 2 million monthly active users within three years and expecting "Hydrogen Ion" to break even in 2029. The firm has lowered Ali Health's target price from 6 Hong Kong dollars to 5.3 Hong Kong dollars to reflect variables such as commercialization speed, but maintains a "buy" rating.